RXC007 for IPF Showing Favorable Safety in Ongoing Phase 1 Trial

RXC007 for IPF Showing Favorable Safety in Ongoing Phase 1 Trial

309006

RXC007 for IPF Showing Favorable Safety in Ongoing Phase 1 Trial

RXC007, an investigational oral therapy for idiopathic pulmonary fibrosis (IPF), is showing favorable safety and pharmacological properties in an ongoing Phase 1 trial in healthy volunteers. The experimental therapy being developed by Redx Pharma works by blocking the activity of ROCK2, a protein involved in a signaling cascade that is thought to promote fibrosis, or tissue scarring, in IPF and other fibrotic conditions. “By inhibiting ROCK2, we believe we’ll be able to impact on numerous pro-fibrotic…

You must be logged in to read/download the full post.